Oxyntomodulin
An endogenous gut hormone that acts as a dual GLP-1/glucagon receptor agonist, suppressing appetite while raising energy expenditure.
Oxyntomodulin (OXM) is an endogenous 37-amino-acid proglucagon-derived peptide co-secreted with GLP-1 and PYY by intestinal L-cells in response to nutrient ingestion. A C-terminal octapeptide extension distinguishes it from GLP-1 and enables dual agonism at both the GLP-1 receptor and the glucagon receptor, combining appetite suppression with increased energy expenditure and glucose homeostasis effects. A 4-week randomized controlled trial in overweight and obese adults established human proof-of-concept for dual GLP-1/glucagon co-agonism as an anti-obesity mechanism, though the native peptide's short half-life has shifted commercial development toward stabilized long-acting analogs such as cotadutide and retatrutide.
Class
Endogenous 37-amino-acid proglucagon-derived peptide (dual GLP-1/glucagon receptor agonist)
Routes
Subcutaneous, Intravenous
Category
Weight Loss & Metabolic
Researched benefits
What it's studied for
Appetite suppression
GLP-1 receptor activation by oxyntomodulin reduces food intake through central satiety signaling. In a 4-week RCT this translated into a significant reduction in energy intake versus placebo.
Increased energy expenditure
Concurrent glucagon receptor activation stimulates thermogenesis in brown adipose tissue and elevates metabolic rate, a mechanism that theoretically produces greater weight loss than GLP-1 activation alone.
Fat oxidation
Glucagon receptor signaling promotes fatty acid oxidation and hepatic metabolic activity, contributing to the reduction in adiposity observed in overweight and obese subjects.
Body weight reduction
In a double-blind RCT, subcutaneous oxyntomodulin reduced body weight by 2.3 kg over four weeks versus 0.5 kg for placebo in overweight and obese adults.
Balanced glycemic effect
The glucogenic glucagon effect and the insulinotropic GLP-1 effect approximately offset each other's glycemic impact, allowing weight loss without the hyperglycemia glucagon alone would cause.
Mechanism
How it works
Oxyntomodulin is generated from the proglucagon precursor in intestinal L-cells and co-released with GLP-1 and PYY after nutrient ingestion. Structurally it is GLP-1 extended by a C-terminal octapeptide, and this extension is what allows it to engage the glucagon receptor in addition to the GLP-1 receptor, making it a dual agonist rather than a selective incretin.
Through the GLP-1 receptor, oxyntomodulin drives central satiety signaling that reduces food intake and slows gastric emptying, producing the appetite-suppressing arm of its action. Through the glucagon receptor, it stimulates hepatic glucose production, brown adipose tissue thermogenesis, and fatty acid oxidation, raising overall energy expenditure.
The combination is metabolically synergistic: appetite suppression lowers caloric intake while elevated energy expenditure increases caloric burn, theoretically yielding greater weight loss than GLP-1 activation alone. Because the glucose-raising glucagon effect and the glucose-lowering GLP-1 effect roughly cancel, net glycemic impact stays balanced.
Native oxyntomodulin is rapidly degraded by DPP-IV, giving it a short plasma half-life that limits its usefulness as a drug in unmodified form. This pharmacokinetic constraint motivated the engineering of stabilized long-acting dual GLP-1/glucagon agonists such as cotadutide, mazdutide, and retatrutide that preserve the same dual mechanism with drug-like durability.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Clinical (RCT protocol)
- Dose
- Escalated subcutaneous dosing
- Frequency
- Three times daily
- Timing
- Before each main meal (pre-prandial)
- Duration
- 4 weeks (study period)
- Route
- Subcutaneous
This pre-meal three-times-daily regimen is the schedule used in the 4-week randomized controlled trial that produced 2.3 kg weight loss; native OXM's short half-life necessitates frequent dosing.
- Native oxyntomodulin is rapidly degraded by DPP-IV, so frequent (three-times-daily) pre-meal administration was required in clinical studies.
- It is used as a research compound only; no standardized consumer dosing protocol or approved product exists.
- Long-acting dual agonist analogs (cotadutide, mazdutide, retatrutide) were developed specifically to replace the frequent-dosing burden of native OXM.
Evidence
Research & clinical studies (5)
Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects
In a 4-week randomized controlled trial, subcutaneous oxyntomodulin three times daily before meals reduced body weight by 2.3 kg versus 0.5 kg for placebo, with reduced energy intake and increased energy expenditure.
PMID 16046306Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy men and women
Investigated how acute moderate-intensity continuous running affects circulating oxyntomodulin concentrations in healthy adults.
PMID 41833829Regulators of Appetite in Mammals - Old and New players
Reviews established and emerging appetite-regulating signals in mammals, situating oxyntomodulin among gut-derived satiety hormones.
PMID 42274231Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes
Maps how layered intellectual property around dual GLP-1/glucagon agonists like mazdutide sustains market exclusivity for next-generation incretin therapeutics built on the oxyntomodulin mechanism.
PMID 41820018Distinctive patterns of glucagon and incretin responses to oral and isoglycaemic intravenous glucose load in fibrocalculous pancreatic diabetes
Characterized glucagon and incretin hormone response patterns to oral versus intravenous glucose loads in fibrocalculous pancreatic diabetes.
PMID 42321243Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Thyroid conditions
- Kidney or liver conditions
- Pregnancy or nursing
Oxyntomodulin carries a moderate risk profile in research contexts. Review all reported contraindications and consult a qualified healthcare professional before any use. Reported considerations are drawn from the source profile and general incretin-agonist class knowledge.
FAQ
Oxyntomodulin — common questions
What is oxyntomodulin?
Oxyntomodulin (OXM) is an endogenous 37-amino-acid proglucagon-derived peptide co-secreted with GLP-1 and PYY by intestinal L-cells after eating. A C-terminal octapeptide extension lets it activate both the GLP-1 receptor and the glucagon receptor, combining appetite suppression with increased energy expenditure and glucose homeostasis effects.
What is oxyntomodulin primarily studied for?
Appetite suppression, energy expenditure, and fat oxidation, all in the context of weight loss and metabolic research.
What does the research show?
A 4-week randomized controlled trial found that subcutaneous oxyntomodulin injected three times daily before meals reduced body weight by 2.3 kg versus 0.5 kg for placebo in overweight and obese adults, alongside reduced energy intake and increased energy expenditure.
How does the dual GLP-1/glucagon mechanism work?
The GLP-1 arm reduces food intake through central satiety signaling, while the glucagon arm raises energy expenditure via brown-fat thermogenesis and fat oxidation. The two glycemic effects roughly offset each other, so weight loss occurs without net hyperglycemia.
Why isn't native oxyntomodulin used as a drug?
Native OXM is rapidly degraded by the enzyme DPP-IV, giving it a very short plasma half-life. This limits its use in unmodified form and has shifted development toward stabilized long-acting analogs such as cotadutide, mazdutide, and retatrutide that use the same dual mechanism.
What are the side effects and contraindications?
Reported contraindications include thyroid conditions, kidney or liver conditions, and pregnancy or nursing. As an incretin-class agonist, nausea and gastrointestinal discomfort are also plausible. This is educational information only; consult a qualified professional before use.
Is oxyntomodulin FDA approved?
No. Native oxyntomodulin has no FDA approval and is classified as investigational and research-only.
